Dyslipidemia in type II diabetes. Implications for therapeutic intervention
Related Experiment Videos
1Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7873.
Insights
Cardiovascular disease is a major risk for type II diabetes patients. While glycemic control shows some benefits, large trials are needed to confirm its impact on cardiovascular mortality and optimize lipid-lowering strategies for diabetics.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Diseases
Background:
- Cardiovascular disease, especially ischemic heart disease, is the leading cause of death and disability in type II diabetes patients.
- Key risk factors for macrovascular complications in diabetes include dyslipidemia, hypertension, and smoking.
- While hyperglycemia is linked to microvascular issues, its role in macrovascular complications is less prominent.
Purpose of the Study:
- To explore the potential benefits of glycemic control on cardiovascular risk in type II diabetes.
- To review the effectiveness of lipid-lowering agents in diabetic subjects.
- To highlight the need for large-scale clinical trials on cardiovascular end points in diabetic populations.
Main Methods:
- Review of existing literature on glycemic control and cardiovascular outcomes in type II diabetes.
- Analysis of the impact of lipid-altering drugs on diabetic patients.
- Examination of characteristic lipid abnormalities in type II diabetes.
Main Results:
- The University Group Diabetes Program trial did not show a cardiovascular mortality benefit from glycemic control in type II diabetes.
- Conventional lipid-lowering agents improve lipid profiles in diabetics, but optimal regimens are undefined.
- Type II diabetes is characterized by hypertriglyceridemia and low high-density lipoprotein cholesterol, which may be significant cardiovascular risk factors in this population.
Conclusions:
- Despite theoretical benefits, empirical evidence on glycemic control reducing cardiovascular mortality in type II diabetes is lacking.
- Metabolic differences in diabetics necessitate tailored lipid-lowering strategies, as some drugs may worsen glucose intolerance.
- There is an urgent need for large-scale trials to assess cardiovascular end points and optimize lipid management in type II diabetes, as these patients are often excluded from current trials.
Abstract:
Cardiovascular disease, and in particular ischemic heart disease, is the principal cause of morbidity, functional disability, and mortality in patients with non-insulin-dependent (type II) diabetes. The main risk factors for the macrovascular complications of diabetes are dyslipidemia, hypertension, and cigarette smoking. Although degree of hyperglycemia is a risk factor for microvascular complications, it is not a prominent risk factor for macrovascular complications. Nevertheless, there are theoretical reasons for believing that glycemic control could lower cardiovascular risk. For example, glycemic control may both improve clearance and suppress hepatic overproduction of very-low-density lipoprotein. Moreover, there is direct empirical evidence that improved glycemic control can favorably alter lipid profiles in type II diabetic patients. Despite this, the only clinical trial that has assessed cardiovascular mortality as an end point in diabetic subjects (i.e., the University Group Diabetes Program) failed to demonstrate a benefit of glycemic control. In this study, the insulin-variable group, which achieved sustained glycemic control relative to the placebo group, had essentially the same cardiovascular mortality as the latter group. All of the conventional lipid-lowering agents have been shown to produce favorable changes in lipid profiles in diabetic subjects. However, the optimum regimen remains to be defined. Metabolic differences between diabetic and nondiabetic subjects mean that the optimum lipid-lowering regimens for the two categories of patients may differ. For example, nicotinic acid, which is a powerful lipid-altering drug, may worsen glucose intolerance. The characteristic lipid abnormalities in type II diabetic subjects are hypertriglyceridemia and low high-density lipoprotein cholesterol, not hypercholesterolemia. Although the role of hypertriglyceridemia as a cardiovascular risk factor in the general population has been questioned, there is evidence that this lipid abnormality may play a stronger role in diabetic subjects. For all of the above reasons, there is an urgent need for large-scale clinical trials assessing cardiovascular end points and testing various strategies of improving lipid profiles in diabetic subjects, particularly given the fact that all of the current generation of lipid-lowering trials have systematically excluded diabetic patients.